Leucovorin and 5-fluorouracil as a treatment for disseminated cancer of the pancreas and unknown primary tumors

Chemotherapy with leucovorin (100 to 200 mg) and 5-fluorouracil (30 mg/kg) every 2 wk produced four (three complete) objective responses among a group of eight patients with early metastatic pancreatic primary and unknown cancers. Complete remissions were associated with exceptionally long durations...

Full description

Saved in:
Bibliographic Details
Published in:Cancer research (Chicago, Ill.) Ill.), 1988-10, Vol.48 (19), p.5570-5572
Main Authors: BRUCKNER, H. W, CROWN, J, MCKENNA, A, HART, R
Format: Article
Language:English
Subjects:
Adult
Aged
Antineoplastic agents
Antineoplastic Combined Chemotherapy Protocols - therapeutic use
Biological and medical sciences
Bone Neoplasms - secondary
Chemotherapy
Clinical Trials as Topic
Fluorouracil - administration & dosage
Humans
Leucovorin - administration & dosage
Liver Neoplasms - secondary
Lung Neoplasms - secondary
Lymphatic Metastasis
Medical sciences
Middle Aged
Neoplasms, Unknown Primary
Pancreatic Neoplasms - drug therapy
Pharmacology. Drug treatments
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Chemotherapy with leucovorin (100 to 200 mg) and 5-fluorouracil (30 mg/kg) every 2 wk produced four (three complete) objective responses among a group of eight patients with early metastatic pancreatic primary and unknown cancers. Complete remissions were associated with exceptionally long durations of survival, one in a patient failing prior combination chemotherapy. This treatment warrants testing because of its ease, scientific rationale, and the large population of patients with early metastatic pancreatic cancer for whom there is no accepted treatment. Early metastatic disease is defined as small metastatic lesions not immediately life threatening found in a physiologically intact patient. Controlled trials, demonstrating benefit associated with other 5-fluorouracil-containing regimens for patients with nonmetastatic stages of pancreatic cancer, provide a rationale for extending testing of leucovorin and 5-fluorouracil to other early stages of pancreatic cancer.
ISSN:0008-5472
1538-7445